AI and machine learning are shaking up drug discovery, cutting down research timelines, slashing costs, and uncovering new treatment possibilities at an unprecedented pace. Traditional drug development takes over a decade and costs billions, but AI is changing the game- streamlining drug candidate identification, optimising formulations, and improving clinical trial efficiency. However, with AI playing a bigger role in the inventive process, the big question is: who (or what) gets credit for the innovation?
Patent laws still require a human inventor, making it tricky to protect AI-generated discoveries. Regulators are starting to tackle the issue, but there’s a lot of uncertainty around how much human involvement is needed to secure a patent. Meanwhile, AI’s influence goes beyond discovery- it’s driving breakthroughs in biomarkers, personalised medicine, and pharma manufacturing. Companies need a strong IP strategy to make sure they stay protected while navigating this evolving legal landscape.
This session dives into the latest developments in AI-powered drug discovery, the shifting patent landscape, and what it all means for your IP strategy exploring key themes such as:
- AI-Powered Drug Discovery & Patents: How AI is transforming the hunt for new drugs and reshaping IP protection
- The Inventorship Dilemma: Can AI be an inventor? How regulators are handling this hot-button issue
- Obviousness & Patentability Challenges: Addressing the hurdles of proving AI-generated innovations are truly novel and non-obvious
- Smart Patent Strategies for AI Innovations: Securing IP for AI-assisted formulations, biomarkers, and repurposed drugs
- Building a Bulletproof IP Strategy: Protecting your AI-driven breakthroughs and staying competitive in the life sciences space
Join us for an insightful discussion on the challenges and opportunities AI presents in drug discovery. In this fast-moving field, staying ahead means knowing how to protect what matters.